Codexis has joined the year-end rush to file an IPO. The biotech company, which produces enzymes, microbes and other industrial catalysts for drugmakers and companies in the energy and environmental fields, plans to raise $100 million through its initial public offering. Some of that money could be used to buy up new technologies, as well as increase the company's production capacity. In the first nine months of this year, Codexis saw its revenue swell by 84 percent.
The Redwood City, CA-based biotech's clients include Dr. Reddy's Laboratories, Merck, Pfizer and Ranbaxy Laboratories. No date has been set for the IPO, and Codexis didn't spell out how many shares it plans to sell. Shares will trade on Nasdaq under CDXS.